ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

APH Alliance Pharma Plc

44.15
0.15 (0.34%)
Last Updated: 15:38:19
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma Plc LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.15 0.34% 44.15 44.00 44.50 45.45 43.00 45.45 496,668 15:38:19
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 180.68M -33.14M -0.0613 -7.09 237.85M
Alliance Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker APH. The last closing price for Alliance Pharma was 44p. Over the last year, Alliance Pharma shares have traded in a share price range of 24.55p to 50.00p.

Alliance Pharma currently has 540,565,539 shares in issue. The market capitalisation of Alliance Pharma is £237.85 million. Alliance Pharma has a price to earnings ratio (PE ratio) of -7.09.

Alliance Pharma Share Discussion Threads

Showing 3126 to 3146 of 3775 messages
Chat Pages: Latest  127  126  125  124  123  122  121  120  119  118  117  116  Older
DateSubjectAuthorDiscuss
15/4/2024
10:01
Does anybody have a view apart from Blackhorse.
Debt coming down but does it still dominate the figures and are banks comfortable. Will they still need to pass dividend?
TIA

trustman
14/4/2024
13:41
Announcement on 23rd , record revenues , record profits & dividends reinstatement
blackhorse23
13/4/2024
17:26
Yeh right.. move money elsewhere no divi as debt is too high!!
maverick67
12/4/2024
09:04
Closing 39p
blackhorse23
11/4/2024
08:09
Excellent Blue sky today
blackhorse23
10/4/2024
22:12
AlliancePharma has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEND +5% -PORTFOLIO BROADENED THROUGH ACQUISITION
blackhorse23
10/4/2024
20:33
I must confess I am developing a vicarious fascination with this guy ; here are his afternoon's APH rampings:

Blackhorse23 - 10 Apr 2024 - 15:23:54 - 5102 of 5111 Harvest Minerals at UK Investor Show - HMI
Money moving to APH [alliance pharma] , dividend announcement in 7 days
Blackhorse23 - 10 Apr 2024 - 15:23:43 - 546 of 548 Redx Pharma PLC - REDX
Money moving to APH [alliance pharma] , dividend announcement in 7 days
Blackhorse23 - 10 Apr 2024 - 15:22:30 - 71 of 75 RGT - To appear in February Medical Journal - Could Easily Double - RGT
Money moving to APH [alliance pharma] , dividend announcement in 7 days
Blackhorse23 - 10 Apr 2024 - 15:22:09 - 11367 of 11369 FEEDBACK plc Medical Imaging Technology - FDBK
Money moving to APH [alliance pharma] , dividend announcement in 7 days
Blackhorse23 - 10 Apr 2024 - 15:21:46 - 20885 of 20889 FUTURA a winner for 2015 - FUM
Money moving to APH [alliance pharma] , dividend announcement in 7 days
Blackhorse23 - 10 Apr 2024 - 15:21:08 - 90 of 92 :::: DOWLAIS GROUP :::: - DWL
Money moving to APH , dividend announcement in 7 days
Blackhorse23 - 10 Apr 2024 - 15:20:46 - 3023 of 3024 Unilever - The Dream and Safe Ticket - ULVR
Money moving to APH , dividend announcement in 7 days
Blackhorse23 - 10 Apr 2024 - 15:20:08 - 1196 of 1197 Anglo American - Global Mining Group - AAL
Money moving to APH , dividend announcement in 7 days


He isn't even right about the results announcement , they are on the 23rd...

wad collector
10/4/2024
19:10
I think they will be paying down their debt as interest rates must be hurting their debt bad, dividend cancellation would certainly be on the cards more likely than not. Black donkey 30-40% uplift on results days that he told the new investor Jerry mouse is disgraceful. I sincerely hope Jerry did not buy as he's already lost 5% and likely to loose another 30% when the auditing is finally finished. That would mean he'd need at least a 60% rise just to break even. Idiots like Blackhorse prey on the naivety of investors so he can trade the share and constantly buy sell and make those 975 top ups he's sondes these past 6 months Guys a muppet
tomzimerman
10/4/2024
18:02
Dividend cancellation again
kpe
10/4/2024
14:44
Dividend announcements on 23rd
blackhorse23
10/4/2024
14:29
Money moving to DWL.
blueball
10/4/2024
12:07
Quite a reasonable target
tomzimerman
09/4/2024
18:09
Bid for 100p per share not 60p. Since then YTT revenues up by 16% & profit went up as well
blackhorse23
09/4/2024
16:38
Nothing has changed since the bid for 60p last year.
justiceforthemany
09/4/2024
15:57
Quite a way to drop yet! 20p target.
the imperialist
09/4/2024
15:56
Sold here and bought a t shirt
tomzimerman
09/4/2024
15:34
Sell while you can bought FDEV
maverick67
09/4/2024
13:27
Ha ha ha, yes sooooo depressed, topppng up a share at the same price over 100times And I'm depressed ?
tomzimerman
09/4/2024
10:48
Full Year Trading Update Strong revenues on H2 recovery, leverage reduced Alliance Pharma plc (AIM: APH), the international healthcare group, announces its trading update for the year ended 31 December 2023 (the "Period"), ahead of the announcement of the Group's audited results in March 2024, which are anticipated to be in line with market expectations.Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations.
blackhorse23
09/4/2024
10:47
And that’s despite todays results
solarno lopez
09/4/2024
10:44
Just joining the thread so bear with me when I ask, what caused the dramatic fall from 1.20 to 40p.

A one liner will do thanks

solarno lopez
Chat Pages: Latest  127  126  125  124  123  122  121  120  119  118  117  116  Older

Your Recent History

Delayed Upgrade Clock